SCHEMBL2664679

SCHEMBL2664679

Cc1ccccc1CNc1cc(OCCc2scnc2C)cc(C(=O)Nc2nncs2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
RAB9A P51151 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
PPARG P37231 1/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 2/20 0.37
NPSR1 Q6W5P4 1/20 0.36
ABL1 P00519 1/20 0.35
SRC P12931 1/20 0.35
AQP4 P55087 1/20 0.35
HPGD P15428 2/20 0.35
MAPK1 P28482 1/20 0.35
NPC1 O15118 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMT2A Q03164 1/20 0.35
MAPK14 Q16539 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664666 0.88 KDM4E (0.42) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664738 0.86 SCD (0.40) RAB9APPARGABL1SRCNPC1
SCHEMBL5427634 0.84 GCK (0.51)
SCHEMBL2664559 0.81 RAB9A (0.46) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664553 0.80 KDM4E (0.47) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664675 0.79 GCK (0.44) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664620 0.79 RAB9A (0.43) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664560 0.78 RAB9A (0.43) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664588 0.77 KMT2A (0.50) LMNAKDM4EMAPTTSHRRAB9A
SCHEMBL2664712 0.77 GCK (0.47) KDM4ERAB9AALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 LMNA 1802/4885KDM4E 2280/4885MAPT 4022/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 LMNA 1802/4885KDM4E 2280/4885MAPT 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.